BR112023023002A2 - EXTENDED REGIMES OF HIGH-DOSE VEGF ANTAGONISTS FOR TREATMENT OF ANGIOGENIC EYE DISEASES - Google Patents

EXTENDED REGIMES OF HIGH-DOSE VEGF ANTAGONISTS FOR TREATMENT OF ANGIOGENIC EYE DISEASES

Info

Publication number
BR112023023002A2
BR112023023002A2 BR112023023002A BR112023023002A BR112023023002A2 BR 112023023002 A2 BR112023023002 A2 BR 112023023002A2 BR 112023023002 A BR112023023002 A BR 112023023002A BR 112023023002 A BR112023023002 A BR 112023023002A BR 112023023002 A2 BR112023023002 A2 BR 112023023002A2
Authority
BR
Brazil
Prior art keywords
treatment
extended
regimes
vegf antagonists
eye diseases
Prior art date
Application number
BR112023023002A
Other languages
Portuguese (pt)
Inventor
J Berliner Alyson
Friedrich Asmus
Karen Chu
D Rittenhouse Kay
L Vitti Robert
Casimiro Da Silva Leal Sergio
Thomas Eissing
Original Assignee
Bayer Healthcare Llc
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Regeneron Pharma filed Critical Bayer Healthcare Llc
Publication of BR112023023002A2 publication Critical patent/BR112023023002A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

regimes estendidos de antagonistas de vegf em altas doses para tratamento de doenças oculares angiogênicas. a presente invenção refere-se a regimes de tratamento particularizados por altas doses de aflibercept (por exemplo, 8 mg) e intervalos prolongados entre as doses (por exemplo, 12 semanas) com melhores resultados visuais e anatômicos em relação ao tratamento com doses mais baixas, como 2 mg.extended regimens of high-dose vegf antagonists for treatment of angiogenic ocular diseases. The present invention relates to treatment regimens characterized by high doses of aflibercept (e.g., 8 mg) and prolonged intervals between doses (e.g., 12 weeks) with improved visual and anatomical results compared to treatment with lower doses. , such as 2 mg.

BR112023023002A 2021-05-17 2022-05-16 EXTENDED REGIMES OF HIGH-DOSE VEGF ANTAGONISTS FOR TREATMENT OF ANGIOGENIC EYE DISEASES BR112023023002A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US202263306315P 2022-02-03 2022-02-03
PCT/US2022/029462 WO2022245739A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
BR112023023002A2 true BR112023023002A2 (en) 2024-01-23

Family

ID=81975181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023002A BR112023023002A2 (en) 2021-05-17 2022-05-16 EXTENDED REGIMES OF HIGH-DOSE VEGF ANTAGONISTS FOR TREATMENT OF ANGIOGENIC EYE DISEASES

Country Status (13)

Country Link
US (1) US20230302085A1 (en)
EP (1) EP4185318A1 (en)
JP (1) JP2024519629A (en)
KR (1) KR20240008821A (en)
AU (1) AU2022275786A1 (en)
BR (1) BR112023023002A2 (en)
CA (1) CA3190663A1 (en)
CL (1) CL2023003396A1 (en)
IL (1) IL308505A (en)
MX (1) MX2023013554A (en)
PE (1) PE20240922A1 (en)
TW (1) TW202313095A (en)
WO (1) WO2022245739A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023135645A (en) * 2022-03-15 2023-09-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
WO2023177691A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN100502945C (en) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Application of fusion protein of VEGF receptor for treating disease of eye
KR20220097542A (en) * 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. Use of a vegf antagonist to treat angiogenic eye disorders
TWI705827B (en) * 2014-11-07 2020-10-01 瑞士商諾華公司 Methods for treating ocular diseases
BR112018013805A2 (en) * 2016-01-08 2018-12-11 Clearside Biomedical, Inc. methods and devices for the treatment of aflibercept posterior eye disorder and other biological products
EP4279135A3 (en) * 2017-11-30 2024-02-21 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat diabetic retinopathy
CN117065151A (en) 2017-12-13 2023-11-17 里珍纳龙药品有限公司 Device and method for accurate dose delivery
MA52570A (en) 2018-05-10 2021-03-17 Regeneron Pharma FORMULATIONS CONTAINING HIGH CONCENTRATION VEGF RECEPTOR FUSION PROTEINS
AU2020289563A1 (en) 2019-06-05 2022-01-20 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
JP2022547681A (en) * 2019-09-12 2022-11-15 ルピン・リミテッド Modified Dosing of VEGF Inhibitors for Ophthalmic Use

Also Published As

Publication number Publication date
CL2023003396A1 (en) 2024-06-07
AU2022275786A1 (en) 2023-04-06
PE20240922A1 (en) 2024-04-30
JP2024519629A (en) 2024-05-21
CA3190663A1 (en) 2022-11-24
US20230302085A1 (en) 2023-09-28
WO2022245739A1 (en) 2022-11-24
AU2022275786A8 (en) 2023-06-01
MX2023013554A (en) 2023-11-29
KR20240008821A (en) 2024-01-19
TW202313095A (en) 2023-04-01
EP4185318A1 (en) 2023-05-31
IL308505A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
BR112023023002A2 (en) EXTENDED REGIMES OF HIGH-DOSE VEGF ANTAGONISTS FOR TREATMENT OF ANGIOGENIC EYE DISEASES
BR112018008358A2 (en) ? compositions and methods for fecal microbiota-related therapy?
CL2017001117A1 (en) Methods to treat eye diseases.
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
CO2021006672A2 (en) Nlrp3 modulators
BR112015007778A2 (en) vegf neutralizing prodrugs for the treatment of eye conditions
MX2021006092A (en) Use of a vegf antagonist to treat angiogenic eye disorders.
BR112022007677A2 (en) RECOMBINANT L-ASPARAGINASE
BR112017002637A2 (en) methods to treat or prevent eye conditions
BR112016000546A2 (en) methods to treat or prevent eye conditions
EA201492031A1 (en) METHODS OF TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMOLOGICAL DISEASES
CO2021014008A2 (en) Pharmaceutical Compounds for the Treatment of Complement-Mediated Disorders
CO2020000227A2 (en) Nlrp3 modulators
BR112021019931A2 (en) Systemic isoxazoline parasiticides for treatment or prophylaxis of vector-borne and viral disease
CL2020001495A1 (en) Compositions and method for the treatment of metabolic diseases
EA202191684A1 (en) DRUG CONTAINING URSODEOXYCHOLIC ACID FOR TREATMENT OR PREVENTION OF PRESBIOPIA
AR112538A1 (en) METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
CO2021015265A2 (en) Compositions and methods of oxymetazoline for the treatment of ocular disorders
BRPI0517972A (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of eye diseases and diseases associated with hyperproliferative and angiogenic responses
BR112017008805A2 (en) corneal treatment using laminin
BR112019004791A2 (en) multiple sclerosis treatment with chs-131
WO2021090070A3 (en) Metered dose for disorders in or around the eye
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
BR112021025701A2 (en) Isoxazoline parasiticide formulations and methods to treat blepharitis
BR112019002355A2 (en) compositions and methods for stroke prevention in pediatric patients with sickle cell anemia